Alvotech (ALVO)
NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$3.14
▲ +4.84%
Market Cap
$979.8M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.21
52-Wk Range
2.94-11.12
CEO
Lisa Graver
Country
IS
Currency
USD
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's dis…
Open full interactive analysis & DCF →